drugset / Trial / NCT06690827
Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN
NaSingle-groupOpen-labelTreatment
Summary
This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors.
Timeline
- Start
- 2024-11-13
- Primary completion
- 2027-10-30
- Completion
- 2028-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-CD123 CAR NK cells | Cell therapy | 1e+07 cells/kg | — |
| Subject | Anti-CD123 CAR NK cells | Cell therapy | 3e+07 cells/kg | — |
| Subject | Anti-CD123 CAR NK cells | Cell therapy | 5e+07 cells/kg | — |